antidiabetic drugs  

Albiglutide - Alogliptin - Canagliflozin - Dapagliflozin - Empagliflozin - Exenatide - Glipizide - Glyburide - Liraglutide - Lixisenatide - Metformin - Nateglinide - Pioglitazone - Rosiglitazone - Saxagliptin - Sitagliptin - Sulfonylurea - Taspoglutide - Troglitazone - Voglibose      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

diabetes type 2

albiglutide
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET)NCT00518115Exploratory suggesting
alogliptin
Nauck, 2009alogliptinplacebo (add on MET)NCT00286442Low risk of bias negative
dapagliflozin
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NCT00528879Low risk of bias -
glimeripide
Study 201 (Goldberg), 1996glimepirideplaceboLow risk of bias -
Schade, 1998glimepirideplaceboLow risk of bias -
Rosenstock, 1996glimepirideplaceboLow risk of bias -
Luis Bautista, 2003glimepirideplaceboLow risk of bias -
Kaneko, 1993glimepirideplacebo -
Study 202glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Charpentier, 2001glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996glimepirideglibenclamideLow risk of bias -
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Inukai, 2005glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Dills, 1996glimepirideglyburideLow risk of bias -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburideLow risk of bias -
Simonson, 1997glipizideplaceboLow risk of bias -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET)Low risk of bias -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003glyburidecontrol (add on MET) -
Garber, 2002glyburideplaceboLow risk of bias -
Vray, 1995glyburideplaceboLow risk of bias -
linagliptin
Gallwitz, 2012linagliptinglimepiride (add on MET)NCT00622284Low risk of bias -
linagliptin 1218.62 ongoing linagliptin low doselinagliptinNCT01012037Low risk of bias ongoing
OwenslinagliptinMetformin + sulfonylureaNCT00602472 -
Del PratolinagliptinplaceboNCT00621140Low risk of bias -
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET)NCT01215097Low risk of bias ongoing
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD)NCT00996658 ongoing
Lewin, 2010linagliptinplacebo (add on SU)NCT00819091Low risk of bias -
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazoneNCT01183013 ongoing
liraglutide
NN2211-1799 ongoing liraglutide other dosesplaceboNCT00620282Low risk of bias ongoing
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)NCT00318461Low risk of bias suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NCT00395746Low risk of bias ongoing
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)NCT00331851Low risk of bias suggesting
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NCT01296412 ongoing
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SUNCT00518882Risk of bias suggesting
Seino, 2010liraglutide other dosesglibenclamideNCT00393718Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NCT00318461Low risk of bias negative
EAGLE ongoing liraglutide other dosesinsulin glargineNCT01117350 ongoing
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)NCT00331851Risk of bias negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)NCT00318422Low risk of bias suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptinNCT00700817Risk of bias suggesting
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptinNCT00700817Low risk of bias suggesting
lixisenatide
GETGOAL-Llixisenatideplacebo (add on basal insulin)NCT00715624Low risk of bias -
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin)NCT00975286Low risk of bias ongoing
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin)NCT00866658Low risk of bias ongoing
Ratner DRI6012, 2010lixisenatideplacebo (add on MET)NCT00299871Exploratory -
GETGOAL-M ongoing lixisenatideplacebo (add on MET)NCT00712673Low risk of bias ongoing
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU)NCT01169779Low risk of bias ongoing
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET)NCT00713830Low risk of bias ongoing
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET)NCT00763815Low risk of bias ongoing
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET)NCT00976937Low risk of bias ongoing
mitiglinide
GaomitiglinidenateglinideNCT00461617Low risk of bias -
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002nateglinideplaceboLow risk of bias -
Horton, 2000nateglinideplaceboLow risk of bias -
Hanefeld, 1990nateglinideplaceboLow risk of bias -
Saloranta, 2002nateglinideplaceboLow risk of bias -
Mari, 2005nateglinideplacebo -
Moses, 2001nateglinideplaceboLow risk of bias -
Goldberg, 1998repaglinideplaceboLow risk of bias -
Jovanovic, 2000repaglinideplaceboLow risk of bias -
Bech, 2003repaglinideplaceboLow risk of bias -
Li, 2009nategliniderepaglinide -
Li, 2007nategliniderepaglinide -
Ristic, 2006nateglinidegliclazide (add on MET)Low risk of bias -
pioglitazone
PNFP-014pioglitazone + insulinplacebo (add on insulin)Exploratory negative
OPI-502pioglitazone + insulinplacebo (add on insulin)Exploratory negative
repaglinide
Moses, 1999repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999repaglinideglibenclamideLow risk of bias -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamideLow risk of bias -
Madsbad, 2001repaglinideglipizideLow risk of bias -
Lund, 2007repaglinidemetforminLow risk of bias -
Raskin, 2001repaglinideon top pioglitazone -
Raskin, 2001repaglinideon top rosiglitazone -
Raskin, 2000repaglinideon top troglitazone -
Chuang, 1999repaglinideplacebo -
Goldberg, 1998repaglinideplaceboExploratory -
Jovanovic, 2000repaglinideplaceboLow risk of bias -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
rosiglitazone
SB-712753/009 rosiglitazoneExploratory -
49653/136 rosiglitazoneplaceboExploratory -
BRL 49653/347 rosiglitazoneplacebo (add on insulin)NCT00054782Exploratory -
49653/085 rosiglitazoneplacebo (add on insulin)Exploratory -
49653/095 rosiglitazoneplacebo (add on insulin)Exploratory -
saxagliptin
saxgliptin, renal studysaxagliptinplacebo (add on current treatment) -
CV181-057saxagliptinplacebo (add on insulin)NCT00757588 -
DeFronzo, 2009saxagliptinplacebo (add on MET)NCT00121667negative
CV181-080saxagliptinplacebo (add on MET)NCT00885378 -
Jadzinsky, 2009saxagliptinplacebo (add on MET)NCT00327015 -
CV181-066saxagliptinplacebo (add on MET)NCT00683657 -
Hollandersaxagliptinplacebo (add on TZD)NCT00295633 -
Rosenstock, 2008saxagliptinplacebo (monotherapy)NCT00950599 -
CV181-011saxagliptinplacebo (monotherapy)NCT00121641 -
CV181-038saxagliptinplacebo (monotherapy)NCT00316082 -
CV181-041saxagliptinplacebo (monotherapy)NCT00374907 -
saxagliptin vs sitagliptinsaxagliptinsitagliptin (add on MET) -
sitagliptin
Charbonnel, 2006sitagliptinplacebo (add on MET)NCT0086515negative
Nauck, 2007sitagliptinplacebo (add on MET)NCT00094770negative
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)negative
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)NCT00086502suggesting
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)negative
taspoglutide
BC21713 (vs placebo) ongoing taspoglutideplaceboNCT00754988Low risk of bias ongoing
BC20963 ongoing taspoglutideplaceboNCT00744367Low risk of bias ongoing
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplaceboNCT00423501Exploratory suggesting
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET)NCT00460941Exploratory suggesting
BC22092 ongoing taspoglutideplacebo (add on MET)NCT00823992Low risk of bias ongoing
BC21625 ongoing taspoglutideexenatideNCT00717457 ongoing
ZC22565 ongoing taspoglutideinsulin glargineNCT01051011 ongoing
BC20965 ongoing taspoglutideinsulin glargine (add on MET)NCT00755287 ongoing
BC21893 ongoing taspoglutidepioglitazoneNCT00909597Low risk of bias ongoing
vildagliptin
Fonseca, 2007vildagliptinplacebo (add on insulin)NCT00099931Low risk of bias suggesting
Ahren, 2004vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007vildagliptinplacebo (add on MET)NCT00099892Low risk of bias negative
Goodman, 2009vildagliptinplacebo (add on MET)Low risk of bias negative
Garber, 2007vildagliptinplacebo (on top pioglitazone)NCT00099853negative
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET)NCT00106340Low risk of bias suggesting
Bolli, 2008vildagliptinpioglitazone (add on MET)NCT00237237Low risk of bias negative
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NCT00101803Low risk of bias negative